NASDAQ-listed clinical-stage biotech mining human aging data to discover metabolic and inflammatory-aging drugs.
Swiss aging-biotech (formerly Rejuveron) building a portfolio of therapeutics targeting the hallmarks of aging.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →